![](/images/graphics-bg.png)
Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
Joint Authors
Guerriero, F.
Ferrari, M. E.
Botta, F.
Fioroni, F.
Grassi, E.
Sarnelli, A.
Pacilio, M.
Amato, E.
Strigari, L.
Bodei, L.
Iori, M.
Pedroli, G.
Cremonesi, M.
Paganelli, Giovanni
Versari, A.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-06-20
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Kidney dosimetry in 177Lu and 90Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is considered time and resource consuming.
We investigated the most adequate timing for imaging and time-activity interpolating curve, as well as the performance of a simplified dosimetry, by means of just 1-2 scans.
Finally the influence of risk factors and of the peptide (DOTATOC versus DOTATATE) is considered.
28 patients treated at first cycle with 177Lu DOTATATE and 30 with 177Lu DOTATOC underwent SPECT scans at 2 and 6 hours, 1, 2, and 3 days after the radiopharmaceutical injection.
Dose was calculated with our simplified method, as well as the ones most used in the clinic, that is, trapezoids, monoexponential, and biexponential functions.
The same was done skipping the 6 h and the 3 d points.
We found that data should be collected until 100 h for 177Lu therapy and 70 h for 90Y therapy, otherwise the dose calculation is strongly influenced by the curve interpolating the data and should be carefully chosen.
Risk factors (hypertension, diabetes) cause a rather statistically significant 20% increase in dose (t-test, P<0.10), with DOTATATE affecting an increase of 25% compared to DOTATOC (t-test, P<0.05).
American Psychological Association (APA)
Guerriero, F.& Ferrari, M. E.& Botta, F.& Fioroni, F.& Grassi, E.& Versari, A.…[et al.]. 2013. Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors. BioMed Research International،Vol. 2013, no. 2013, pp.1-12.
https://search.emarefa.net/detail/BIM-1031118
Modern Language Association (MLA)
Guerriero, F.…[et al.]. Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors. BioMed Research International No. 2013 (2013), pp.1-12.
https://search.emarefa.net/detail/BIM-1031118
American Medical Association (AMA)
Guerriero, F.& Ferrari, M. E.& Botta, F.& Fioroni, F.& Grassi, E.& Versari, A.…[et al.]. Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-12.
https://search.emarefa.net/detail/BIM-1031118
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1031118